Comparison of Treatments for Hepatocellular Carcinoma Patients with Portal Vein Thrombosis: a Systematic Review and Network Meta-analysis

Overview

Journal Ann Transl Med

Publisher AME Publishing Company

Date 2021 Nov 4

PMID 34734002

Citations 3

Authors

Jianchen Luo

Liangliang Xu

Lian Li

Jingfu Zhang

Ming Zhang

Mingqing Xu

Affiliations

Soon will be listed here.

Abstract

Background: Sorafenib, hepatectomy, and transarterial chemoembolization (TACE) are the recommended treatment for portal vein tumor thrombosis (PVTT) patients. Therefore, the aim of the present study was to conduct a multi-treatment meta-analysis. The aim of the present study was to analyze the survival benefit of different treatments options on PVTT patients.

Methods: We systematically analyzed 12 randomized controlled trials (4,265 participants) from 2012 to 2019, which compared any of the following treatment options on PVTT patients: TACE, sorafenib, hepatectomy, sorafenib + TACE, hepatectomy + TACE, and sorafenib + hepatectomy. The main outcome was the 1-year survival rate of patients.

Results: The results of the rank probability of effectiveness showed that sorafenib + TACE was more likely to be the most effective treatment, sorafenib + TACE group was ranged rank 1 when compared with the others [hepatectomy group: odds ratio (OR): 0.79, 95% confidence interval (CI): 0.03-18.26; hepatectomy + TACE group: OR: 0.51, 95% CI: 0.01-13.59; sorafenib group: OR: 0.14, 95% CI 0.01-2.29, sorafenib + hepatectomy group: OR: 0.15, 95% CI: 0.00-24.88; and TACE group: OR: 0.51, 95% CI: 0.02-9.88]. The second most effect treatment option was hepatectomy alone.

Discussion: Sorafenib + TACE is more likely to be the most effective treatment option, while hepatectomy alone is the second effective treatment option.

Citing Articles

The Effect of Microvascular Invasion on Hepatocellular Carcinoma With Portal Vein Tumor Thrombus After Hepatectomy: A Retrospective Study.

Xu Q, Lan L, Zeng J, Zeng J Cancer Control. 2024; 31:10732748241265257.

PMID: 39048098 PMC: 11403670. DOI: 10.1177/10732748241265257.

Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis.

Deng J, Liao Z, Gao J Curr Oncol. 2023; 30(1):1243-1254.

PMID: 36661745 PMC: 9858211. DOI: 10.3390/curroncol30010096.

Recent Trends and In-Hospital Mortality of Transarterial Chemoembolization (TACE) in Germany: A Systematic Analysis of Hospital Discharge Data between 2010 and 2019.

Krieg S, Essing T, Krieg A, Roderburg C, Luedde T, Loosen S Cancers (Basel). 2022; 14(9).

PMID: 35565218 PMC: 9100764. DOI: 10.3390/cancers14092088.

References

Llovet J, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J . Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008; 359(4):378-90. DOI: 10.1056/NEJMoa0708857. View

Cheng A, Kang Y, Chen Z, Tsao C, Qin S, Kim J . Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2008; 10(1):25-34. DOI: 10.1016/S1470-2045(08)70285-7. View

Zhang Z, Lai E, Zhang C, Yu H, Liu Z, Wan B . The strategies for treating primary hepatocellular carcinoma with portal vein tumor thrombus. Int J Surg. 2015; 20:8-16. DOI: 10.1016/j.ijsu.2015.05.009. View

Kenjo A, Miyata H, Gotoh M, Kitagawa Y, Shimada M, Baba H . Risk stratification of 7,732 hepatectomy cases in 2011 from the National Clinical Database for Japan. J Am Coll Surg. 2014; 218(3):412-22. DOI: 10.1016/j.jamcollsurg.2013.11.007. View

Poon R, Fan S, Lo C, Liu C, Wong J . Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg. 1999; 229(2):216-22. PMC: 1191634. DOI: 10.1097/00000658-199902000-00009. View

Rabelo C, Feres M, Goncalves C, Figueiredo L, Faveri M, Tu Y . Systemic antibiotics in the treatment of aggressive periodontitis. A systematic review and a Bayesian Network meta-analysis. J Clin Periodontol. 2015; 42(7):647-57. DOI: 10.1111/jcpe.12427. View

. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56(4):908-43. DOI: 10.1016/j.jhep.2011.12.001. View

Wang K, Guo W, Chen M, Mao Y, Sun B, Shi J . Multimodality Treatment for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Large-Scale, Multicenter, Propensity Mathching Score Analysis. Medicine (Baltimore). 2016; 95(11):e3015. PMC: 4839896. DOI: 10.1097/MD.0000000000003015. View

Liang L, Chen T, Li C, Xing H, Han J, Wang M . A systematic review comparing outcomes of surgical resection and non-surgical treatments for patients with hepatocellular carcinoma and portal vein tumor thrombus. HPB (Oxford). 2018; 20(12):1119-1129. DOI: 10.1016/j.hpb.2018.06.1804. View

10.

Chen X, Qiu F, Wu Z, Zhang Z, Huang Z, Chen Y . Effects of location and extension of portal vein tumor thrombus on long-term outcomes of surgical treatment for hepatocellular carcinoma. Ann Surg Oncol. 2006; 13(7):940-6. DOI: 10.1245/ASO.2006.08.007. View

11.

Heimbach J, Kulik L, Finn R, Sirlin C, Abecassis M, Roberts L . AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2017; 67(1):358-380. DOI: 10.1002/hep.29086. View

12.

Zhang Z, Dong K, Zhang E, Zhang L, Chen X, Dong H . Resection might be a meaningful choice for hepatocellular carcinoma with portal vein thrombosis: A systematic review and meta-analysis. Medicine (Baltimore). 2019; 98(50):e18362. PMC: 6922393. DOI: 10.1097/MD.0000000000018362. View

13.

Lee J, Jang B, Lee Y, Choi W, Choi S, Chung W . Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis. Clin Mol Hepatol. 2016; 22(1):160-7. PMC: 4825165. DOI: 10.3350/cmh.2016.22.1.160. View

14.

Peng Z, Guo R, Zhang Y, Lin X, Chen M, Lau W . Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer. 2012; 118(19):4725-36. DOI: 10.1002/cncr.26561. View

15.

Kim G, Shim J, Yoon S, Jung J, Kim J, Ryu M . Comparison of chemoembolization with and without radiation therapy and sorafenib for advanced hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. J Vasc Interv Radiol. 2015; 26(3):320-9.e6. DOI: 10.1016/j.jvir.2014.10.019. View

16.

Zhu H, Ye B, Qiao Z, Zeng L, Li Q . Hepatectomy combined with sorafenib in patients with intermediate-advanced hepatocellullar carcinoma. J BUON. 2019; 24(4):1382-1389. View

17.

Liu P, Lee Y, Hsia C, Hsu C, Huang Y, Chiou Y . Surgical resection versus transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombosis: a propensity score analysis. Ann Surg Oncol. 2014; 21(6):1825-33. DOI: 10.1245/s10434-014-3510-3. View

18.

Takizawa D, Kakizaki S, Sohara N, Sato K, Takagi H, Arai H . Hepatocellular carcinoma with portal vein tumor thrombosis: clinical characteristics, prognosis, and patient survival analysis. Dig Dis Sci. 2007; 52(11):3290-5. DOI: 10.1007/s10620-007-9808-2. View

19.

Zheng N, Wei X, Zhang D, Chai W, Che M, Wang J . Hepatic resection or transarterial chemoembolization for hepatocellular carcinoma with portal vein tumor thrombus. Medicine (Baltimore). 2016; 95(26):e3959. PMC: 4937906. DOI: 10.1097/MD.0000000000003959. View

20.

Zhou Q, Wang Y, Zhou X, Peng B, Yang J, Liang L . Prognostic analysis for treatment modalities in hepatocellular carcinomas with portal vein tumor thrombi. Asian Pac J Cancer Prev. 2012; 12(11):2847-50. View